Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

P46 Takotsubo cardiomyopathy in a GPA patient receiving rituximab therapy

View through CrossRef
Abstract Background Cardiac involvement in GPA is quite rare. Patients with GPA are two times more likely to die of cardiovascular complications as compared to the general population due to accelerated atherosclerosis. Cardiac involvement in GPA is secondary to necrotising vasculitis with granulomatous infiltrates, usually resulting in coronary artery thrombosis. We present a case of Takotsubo cardiomyopathy in a patient of GPA treated with rituximab. There has previously only been one case report of a patient on rituximab therapy developing Takotsubo cardiomyopathy. Methods This 67-year-old woman was diagnosed with GPA in January 2018 when she presented with a necrotic lung lesion along with nasal crusting and leg ulcers. Her ANCA was 102 i.u./ml at the time. We treated with cyclophosphamide and azathioprine to good effect. Then she had a relapse six months later and presented to the hospital with stridor due to subglottic stenosis. At this point we switched to rituximab and methotrexate to induce remission, her ANCA titres settled to 3.4 i.u./ml at this point. After her second cycle of rituximab, she presented to the hospital with shortness of breath, chest pain and stridor in November 2018. Results At her presentation with chest pain in November 2018, an ECG was performed, which showed an incomplete LBBB with ST elevation in anterior leads with a troponin level of 550ng/ml. A repeat ECG after 2 hours, showed ST elevations in anterolateral leads with a troponin level of 1259ng/ml. We treated this as an acute myocardial infarction. An echocardiogram was obtained, which was remarkable in that it showed no new regional wall motion abnormalities. A subsequent coronary angiogram confirmed that there was no coronary artery disease raising the possibility of Takotsubo cardiomyopathy. Conclusion Rituximab is implicated in cardiac arrhythmia and coronary vasospasm during the infusion, reduction in LVEF, non-ischaemic cardiomyopathy, cardiogenic shock after. Our patient had a myocardial infarction with normal coronaries, and she was going through a very emotionally stressful period with her husband’s illness at the time of her presentation, which makes Takatsubo cardiomyopathy a very likely diagnosis. There are few case reports in the literature and, clinicians should be aware of this rare complication. Disclosures S.P. Jayanti None. S. Nair None. D. Makkuni None.
Title: P46 Takotsubo cardiomyopathy in a GPA patient receiving rituximab therapy
Description:
Abstract Background Cardiac involvement in GPA is quite rare.
Patients with GPA are two times more likely to die of cardiovascular complications as compared to the general population due to accelerated atherosclerosis.
Cardiac involvement in GPA is secondary to necrotising vasculitis with granulomatous infiltrates, usually resulting in coronary artery thrombosis.
We present a case of Takotsubo cardiomyopathy in a patient of GPA treated with rituximab.
There has previously only been one case report of a patient on rituximab therapy developing Takotsubo cardiomyopathy.
Methods This 67-year-old woman was diagnosed with GPA in January 2018 when she presented with a necrotic lung lesion along with nasal crusting and leg ulcers.
Her ANCA was 102 i.
u.
/ml at the time.
We treated with cyclophosphamide and azathioprine to good effect.
Then she had a relapse six months later and presented to the hospital with stridor due to subglottic stenosis.
At this point we switched to rituximab and methotrexate to induce remission, her ANCA titres settled to 3.
4 i.
u.
/ml at this point.
After her second cycle of rituximab, she presented to the hospital with shortness of breath, chest pain and stridor in November 2018.
Results At her presentation with chest pain in November 2018, an ECG was performed, which showed an incomplete LBBB with ST elevation in anterior leads with a troponin level of 550ng/ml.
A repeat ECG after 2 hours, showed ST elevations in anterolateral leads with a troponin level of 1259ng/ml.
We treated this as an acute myocardial infarction.
An echocardiogram was obtained, which was remarkable in that it showed no new regional wall motion abnormalities.
A subsequent coronary angiogram confirmed that there was no coronary artery disease raising the possibility of Takotsubo cardiomyopathy.
Conclusion Rituximab is implicated in cardiac arrhythmia and coronary vasospasm during the infusion, reduction in LVEF, non-ischaemic cardiomyopathy, cardiogenic shock after.
Our patient had a myocardial infarction with normal coronaries, and she was going through a very emotionally stressful period with her husband’s illness at the time of her presentation, which makes Takatsubo cardiomyopathy a very likely diagnosis.
There are few case reports in the literature and, clinicians should be aware of this rare complication.
Disclosures S.
P.
Jayanti None.
S.
Nair None.
D.
Makkuni None.

Related Results

A Case of Takotsubo Cardiomyopathy Following Postpartum Hemorrhage in a Patient with Concurrent Influenza A
A Case of Takotsubo Cardiomyopathy Following Postpartum Hemorrhage in a Patient with Concurrent Influenza A
Background Takotsubo cardiomyopathy, also known as stress cardiomyopathy and broken heart syndrome, is a transient, non-ischemic cardiomyopathy marked by revers...
Could rituximab be a silver lining in refractory bone marrow fibrosis caused by lupus?
Could rituximab be a silver lining in refractory bone marrow fibrosis caused by lupus?
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that can present with a variety of clinical manifestations, ranging from mild skin involvement to multisystemic ...
Rituximab-Induced Acute Thrombocytopenia in a Patient with Relapsed Follicular Lymphoma
Rituximab-Induced Acute Thrombocytopenia in a Patient with Relapsed Follicular Lymphoma
Abstract Introduction Rituximab is a well-tolerated monoclonal antibody which is commonly used in the treatment of B cell lymphomas that bear CD20 ant...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash Abstract This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Commensalism or symbiosis: The potential use of rituximab in steroid-refractory Evans syndrome in a patient with ulcerative colitis
Commensalism or symbiosis: The potential use of rituximab in steroid-refractory Evans syndrome in a patient with ulcerative colitis
Evans syndrome (ES) is defined as simultaneous or sequential association of direct Coombs-positive autoimmune hemolytic anemia (AIHA) with superimposed immune-mediated thrombocytop...
Rituximab Use in Children - A Single Center Experience.
Rituximab Use in Children - A Single Center Experience.
Abstract Treatment of children with chronic refractory ITP often results in significant morbidity and current therapies induce remission in fewer than half of childr...

Back to Top